MacroGenics Inc. Reports Q2 2026 Financial Results

What Happened
MacroGenics, Inc. (MGNX) announced its financial and operating results for the quarter ended June 30, 2026, by filing a Form 8-K on August 13, 2026. The company attached a press release reporting those results as Exhibit 99.1 to the filing. The report was signed by Jeffrey Peters, Senior Vice President, General Counsel and Corporate Secretary.

Key Details

• Filing date: August 13, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Period covered: Quarter ended June 30, 2026.
• Press release: Attached as Exhibit 99.1 to the Form 8-K (contains the detailed financial and operating results).
• Disclosure note: The information in the 8-K and Exhibit 99.1 is furnished, not “filed,” and is not subject to Exchange Act Section 18 liability or automatically incorporated by reference into other filings.

Why It Matters
This 8-K signals that MacroGenics has publicly released its latest quarterly results and related operating information—important for shareholders and prospective investors who track revenue, expenses, cash runway, clinical or program updates, and any guidance changes. Investors should read the attached press release (Exhibit 99.1) for the actual figures and details and monitor company filings or earnings calls for additional context.